Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanatinostat + Valganciclovir +/- Pembrolizumab in EBV+ Solid Tumors/NPC
NCT05166577Phase 1Terminated
- Sponsor
- Viracta Therapeutics, Inc.
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, randomised, open-label trial of nanatinostat in nasopharyngeal carcinoma (NPC) and solid tumor (2 arms), sponsored by Viracta Therapeutics, Inc. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Overall Response Rate at 3 years. Started Oct 2021; status: terminated.
02
Drugs
nanatinostat
03
Conditions
nasopharyngeal carcinoma (NPC)solid tumor
Beyond the preview
Go deeper on NCT05166577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166577.